3rd Dec 2015 06:20
LONDON (Alliance News) - GlaxoSmithKline PLC announced that the European Commission has granted marketing authorisation for Nucala or mepolizumab as an add-on treatment for severe refractory eosinophilic asthma in adult patients. As a result Nucala is now approved for use in the 31 European countries covered by the European Medicines Agency or EMA.
Nucala is the first and only approved biologic therapy that targets interleukin-5 (IL-5), which plays an important role in regulating the function of eosinophils, an inflammatory cell known to be important in asthma. It is administered as a 100mg fixed dose subcutaneous injection every four weeks in addition to the patient's normal respiratory medication, which often comprises high-dose inhaled corticosteroids plus additional medicines including oral corticosteroids.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline